Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China.

Haijing GuanYanan ShengWanjie GuoSheng HanLu-Wen Shi

Published in: Advances in therapy (2019)

Alectinib could prolong the mean time of PF and delay the time to CNS progression. However, because of its high drug cost, alectinib was unlikely to be cost-effective for untreated ALK-positive NSCLC patients in China.

Keyphrases

advanced non small cell lung cancer
end stage renal disease
small cell lung cancer
chronic kidney disease
newly diagnosed
prognostic factors
blood brain barrier
emergency department
patient reported
adverse drug